Quest Diagnostics (DGX) is trading lower today as a fresh analyst downgrade weighed on the shares. Citi moved the stock to Neutral from Buy and kept its price target at $185, pointing to reduced visibility into how the company will address its 2026 debt maturities and flagging reputational-risk concerns as an overhang for sentiment.

The downgrade lands ahead of the company’s next quarterly report window and after a period in which DGX had been trading near recent highs, leaving the stock more sensitive to shifts in perceived risk. With the price target below the current share price, the note effectively signals limited near-term upside and encourages investors to wait for clearer evidence around balance-sheet actions and business momentum.

Key swing factors include any company updates on refinancing, debt repayment, or liability management tied to 2026 maturities, plus management commentary around demand trends and margin trajectory. Investors will also focus on whether additional sell-side firms follow with rating changes or price-target resets, which can amplify short-term flows in a defensive healthcare name.